2030 Pharmaceutical Companies Vaccines 
STAT
DECEMBER 13, 2024
Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Meanwhile, the U.S.
pharmaphorum
JANUARY 24, 2023
In this final instalment of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year, three key competitive issues for pharmaceutical companies in 2023 are assessed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 31, 2021
Another recent change is the timelier release of scientific information; rather than holding on to clinical trial findings until the ‘perfect’ opportunity to present them at a major congress, 2020 increasingly saw pharmaceutical companies make data public in real time. What are the associated challenges? Conclusion.
Express Pharma
JUNE 14, 2024
India’s pharmaceutical industry is a global powerhouse. It is already a massive $50 billion market and is projected to grow to $130 billion by 2030. India makes 60 per cent of the world’s vaccines and 20 per cent of the world’s generic drugs. who have sustainability ambitions will also pressure the sector to go green.
Express Pharma
JULY 15, 2024
The government’s initiative to implement a draft strategy aimed at promoting innovation, R&D, and industry-led innovation growth in India’s MedTech and Pharmaceutical industries is a welcome move. This would stimulate new investments in both R&D and production initiatives.
PharmaTech
JULY 4, 2025
Pharmaceutical companies have responded with growing investment in the research and development of novel eye treatments and drug delivery systems designed to address key challenges in ocular therapy. Challener News Article Hydrogels, drug-eluting contact lenses, and other implant technologies show real promise. Siemens Finalizes $5.1B
European Pharmaceutical Review
MAY 21, 2025
It is one of the biggest investments in UK history for a pharmaceutical company. The multi-year partnership with the UK government aims to provide up to 10,000 patients with investigational personalised cancer immunotherapies by 2030, according to the UK governments Department for Science, Innovation and Technology (DSIT).
Expert insights. Personalized for you.
252 
Let's personalize your content